The scientific scope outlined by the society is unusually broad, reflecting how much the discipline has changed since the first annual meeting. According to the announcement, ISSCR 2027 will span breakthroughs in basic biology, advances in disease modeling and drug discovery, and new clinical data on cell-based therapies, with artificial intelligence described as an accelerating force across all three domains. That framing captures a genuine shift in the research landscape. Stem cell science is no longer confined to studies of pluripotency and differentiation; it now encompasses sophisticated organoid and tissue-engineered models of human development, engineering approaches to building biological systems, and a growing pipeline of cell and gene therapies that are producing clinical results in areas ranging from blood disorders to neurological disease. The meeting program is designed to showcase advances across this entire spectrum, from fundamental discoveries about how human tissues form to the engineering of new biological platforms and the evaluation of emerging therapies in patients.

Leadership of the meeting reflects its international character. ISSCR President Lorenz Studer, M.D., founding director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center in the United States, will preside over the Annual Meeting. Studer is widely known for his work on deriving dopamine-producing neurons from stem cells, research that has underpinned clinical efforts to treat Parkinson’s disease with cell replacement therapy. The scientific program itself will be led by two co-chairs drawn from different sides of the Atlantic and different methodological traditions: Viviane Tabar, M.D., of Memorial Sloan Kettering Cancer Center, and Matthias P. Lutolf, Ph.D., of the École Polytechnique Fédérale de Lausanne in Switzerland. Tabar’s background spans neurosurgery and stem cell-based approaches to nervous system disease, while Lutolf is recognized for pioneering work in organoids, engineered stem cell niches, and the microenvironmental cues that control tissue formation. The pairing signals a program intended to bridge clinical translation and fundamental bioengineering.

The structure of the scientific program will combine several formats that have become hallmarks of the meeting. Invited presentations will feature pioneering research from leaders in the field, while a substantial share of the platform presentations will be selected directly from submitted abstracts, a mechanism that gives early career researchers and scientists from less represented institutions a route onto the main program. Interactive poster sessions will run alongside these talks, and the society emphasizes opportunities for collaboration across academia, industry, and clinical research as a central purpose of the gathering. In practice, the meeting serves as the point in the calendar where a graduate student presenting a new organoid protocol can share a poster hall with a biotech executive scouting licensing opportunities and a clinician reporting results from an early phase trial, and the society has built explicit mechanisms to encourage exactly those encounters.

Complementing the scientific sessions, the Exhibit and Poster Hall will spotlight the technological infrastructure that increasingly defines modern stem cell research. The announcement highlights innovations in laboratory automation, advanced imaging, computational technologies, and cell manufacturing as focal points of the exhibition. Each of these areas has become critical to the field’s progress. Automation and robotics are enabling the reproducible, large-scale culture of stem cell lines that manual methods cannot achieve. Advanced imaging allows researchers to track cell fate and tissue morphogenesis in living systems with unprecedented resolution. Computational tools, increasingly augmented by machine learning, are being used to analyze the massive single-cell and spatial datasets that stem cell biology now routinely generates. Cell manufacturing, meanwhile, sits at the heart of the translational challenge: turning a laboratory protocol into a consistent, quality-controlled product suitable for clinical use. By connecting researchers directly with the companies and expertise behind these technologies, the society aims to shorten the distance between discovery and application.

The society has opened several distinct participation pathways, each with its own deadline, and together they reveal how the meeting is being shaped. The most consequential for most attendees is the abstract submission process, which closes on 27 January 2027. Researchers at all career stages are invited to submit their latest findings for consideration as oral or poster presentations, and travel awards are available to ISSCR student and postdoctoral members who submit abstracts, a measure designed to reduce the financial barriers that can keep young scientists from attending international meetings. Given that platform talks selected from abstracts are among the most visible slots at the meeting, the January deadline effectively functions as the first competitive gate of ISSCR 2027, and the society is encouraging submissions across the full breadth of the field rather than restricting them to particular themes.

Early career investigators have additional routes into the meeting’s organization. Applications to become ISSCR 2027 Ambassadors close on 23 October 2026, an unusually early deadline that reflects the ambassador program’s role in outreach and community engagement in the months before the meeting convenes. Ambassadors represent and engage the global stem cell research community in the run-up to the event, extending the meeting’s reach to regions and networks that might otherwise be underrepresented. Student and postdoctoral members can also propose Science Spotlight sessions, with proposals due on 27 January 2027, the same day as the abstract deadline. This mechanism hands junior researchers genuine agenda-setting power, allowing them to highlight emerging research areas, innovative approaches, and new developments that the formal program committee might not otherwise feature. It is a notable inversion of the traditional conference hierarchy, in which program content flows almost entirely from senior committees and invited speakers.

The society has also built in practical support and informal networking structures that acknowledge the realities of attending a four-day international meeting. Eligible ISSCR members can apply for Child and Dependent Care Grants to help offset the costs of care associated with attending in person; applications are due by 10 March 2027, and awards are distributed on a first-come, first-served basis, a detail that effectively rewards early planning. Researchers with shared scientific interests can organize Meet-Up Hubs, informal gatherings held in the Exhibit and Poster Hall, with a deadline of 19 April 2027 for proposals. Finally, the meeting will offer one-on-one partnering, a scheduling service that lets attendees arrange face-to-face meetings with researchers, industry representatives, and potential collaborators to explore scientific partnerships, investments, licensing opportunities, and new ventures. For translational labs and startup-minded investigators, this matchmaking layer is often cited as one of the meeting’s most valuable functions, since it converts a crowded congress into a structured series of targeted conversations.

The choice of San Francisco as host city reinforces the meeting’s translational ambitions. The Bay Area concentrates an exceptional density of academic stem cell research, biotechnology companies, cell therapy developers, and computational biology expertise, and the region has historically been a hub for both the scientific and commercial sides of regenerative medicine. Holding the twenty-fifth anniversary meeting at Moscone West places the global stem cell community at the intersection of those communities. As the announcement puts the matter, ISSCR 2027 will celebrate the legacy of twenty-five years of annual meetings while looking ahead to the discoveries, technologies, and collaborations that will define the future of the field and of human health. Registration and abstract submissions are now open through the meeting’s official site, and with abstracts due in late January 2027, researchers hoping to present their work at the Global Stem Cell Event face a timeline that begins now.

Subject of Research: Registration and abstract submissions for the ISSCR 2027 Annual Meeting on stem cell science and regenerative medicine

Article Title: ISSCR 2027 Annual Meeting opens registration and abstract submissions

Article References: ISSCR 2027 Annual Meeting opens registration and abstract submissions. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ISSCR, stem cell research, annual meeting, regenerative medicine, abstract submissions, San Francisco, cell therapy, organoids, artificial intelligence, disease modeling, cell manufacturing, early career researchers

CAR T-cell therapy is one of the most significant advances in cancer medicine of the past decade. The process begins with the collection of T cells, the immune system’s primary cancer-killing soldiers, from a patient’s own blood. In the laboratory, those cells are genetically modified to express a chimeric antigen receptor, a synthetic molecule that allows the T cell to recognize a specific protein on the surface of cancer cells. Once infused back into the patient, the engineered cells multiply and launch a targeted assault on the tumor. The approach has produced high rates of remission in B-cell blood cancers, a category that accounts for roughly half of all blood cancers and includes lymphomas and certain leukemias.

Despite that success, a major weakness has limited the durability of the treatment. Many patients relapse after CAR T-cell therapy, often within the first year, leaving them with few remaining treatment options. One reason is that the therapy usually targets a single protein, CD19, which plays a central role in B-cell blood cancers. Cancer cells can survive the initial attack by losing or reducing expression of that single target, a phenomenon known as antigen escape. Building on earlier animal studies conducted at other institutions, the Ohio State team designed a therapy that targets three proteins at once: CD19, CD20 and CD22. By forcing the cancer to evade three distinct targets simultaneously, the trispecific construct is intended to make escape far more difficult.

The second innovation in the trial was the use of OX40, an immune costimulatory protein, to strengthen the activity of the engineered cells. According to Sumithira Vasu, MD, professor of hematology and a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, who served as the study’s first and corresponding author, this was the first time a CAR T-cell clinical trial used OX40 to enhance the process and improve tumor death. Costimulatory signals such as OX40 act like an accelerator for T cells, promoting their expansion, persistence and killing capacity after they encounter tumor cells. Vasu noted that results from the trial could lead to better therapeutic outcomes for patients who may have limited options after their B-cell blood cancer has returned or their therapy stopped working.

The trial also addressed a practical challenge that has long troubled the field: manufacturing time. Conventional CAR T-cell production can take weeks, during which aggressive cancers may progress and patients may deteriorate. The Ohio State team used a point-of-care manufacturing process that collected, prepared and returned the cells to the patient in just six days. Critically, the cells were infused fresh rather than frozen, a distinction that some researchers believe preserves the potency of the product. Lapo Alinari, MD, PhD, associate professor of hematology and lead senior co-author of the study, said it has been suggested that fresh cell infusions are preferable, and that the team was able to show the feasibility of rapid manufacturing time and infusion of fresh cells.

The clinical results supported that premise. Alinari reported that the rapid, fresh-cell approach produced meaningful clinical activity with minimal side effects in patients with B-cell non-Hodgkin lymphoma, and achieved remission in mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. These are distinct subtypes of B-cell malignancy with different biological behaviors, and achieving remissions across multiple subtypes suggests the trispecific strategy may have broad applicability. Equally important for an early-phase trial, the therapy was well tolerated, with patients experiencing minimal side effects, an encouraging safety signal for a technology that combines three tumor-targeting domains with an additional immune-boosting element.

Eighteen patients were enrolled in the study, with a median age of 64. Sixteen of them were treated with the OX40-enhanced CAR T-cell product. The patient population reflected the difficult reality of relapsed disease: all enrolled patients had previously received a median of three different types of therapy before receiving the enhanced cell therapy. In other words, these were heavily pretreated individuals whose cancers had already resisted multiple standard approaches, the very group in which new therapies are hardest to evaluate and for whom the unmet need is greatest.

The study was published in Blood Cancer Discovery, a peer-reviewed journal of the American Association for Cancer Research, with the article titled Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22. The research involved a broad team of investigators from Ohio State and Nationwide Children’s Hospital, reflecting the multidisciplinary effort required to move an engineered cell therapy from the laboratory bench to the bedside, including cell processing specialists, biostatisticians, and clinicians across hematology and oncology.

Senior co-author Marcos de Lima, MD, professor of hematology at Ohio State, cautioned that while the trial showed encouraging outcomes for patients with B-cell non-Hodgkin lymphoma treated with the enhanced CAR T-cells, more research in larger patient groups is needed. That caveat is standard and appropriate for a phase I study, which is primarily designed to establish safety and feasibility rather than to definitively measure efficacy. Larger trials will be required to confirm the remission rates, characterize the side-effect profile more completely, and determine whether the OX40 enhancement and trispecific targeting translate into longer-lasting remissions than current single-target products.

Nevertheless, the trial represents a notable step in the evolution of cellular immunotherapy. It combines three strategies that researchers have pursued independently, multi-antigen targeting to prevent immune escape, costimulatory enhancement to strengthen T-cell function, and rapid point-of-care manufacturing to deliver fresh cells before the disease can progress, into a single therapeutic platform. If subsequent studies validate these early findings, the approach could expand the reach of CAR T-cell therapy to patients who currently relapse after standard treatment, and the six-day manufacturing timeline could make this sophisticated form of personalized medicine faster and more accessible for the patients who need it most urgently.

Subject of Research: A first-in-human phase I trial of trispecific OX40-enhanced CAR T-cell therapy for relapsed B-cell blood cancers

Article Title: Clinical trial shows positive results of enhanced CAR T-cell therapy for patients with B-cell blood cancers

Article References: Clinical trial shows positive results of enhanced CAR T-cell therapy for patients with B-cell blood cancers. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: CAR T-cell therapy, B-cell blood cancers, non-Hodgkin lymphoma, CD19, CD20, CD22, OX40, clinical trial, immunotherapy, cell manufacturing, Ohio State University, Blood Cancer Discovery

At the heart of the argument is a well-established biological principle: T cells rewire their metabolism as they activate, proliferate and differentiate. Activated T cells ramp up glycolysis, the process of breaking down glucose for rapid energy and biosynthetic building blocks, a phenomenon first described in leukocytes decades ago. But different metabolic programs produce different T cell fates. Cells burning glucose ferociously tend to become short-lived effector cells, while those relying on mitochondrial respiration and fatty acid oxidation acquire memory-like properties associated with long-term persistence. For a therapy whose success depends on engineered cells remaining alive and functional in the body for weeks or months, steering that metabolic balance is not a side detail. It is central to the therapeutic outcome.

The review highlights that the choice of co-stimulatory domain inside the CAR construct, the molecular module that signals alongside antigen recognition, fundamentally dictates these metabolic fates. The landmark comparison comes from CD28 versus 4-1BB. CAR T cells carrying CD28 signalling drive glycolysis and rapid effector function but tend to exhaust faster, whereas 4-1BB signalling promotes mitochondrial biogenesis and respiratory capacity, supporting memory development and durable persistence. A 2025 study in Cell Reports confirmed that these distinct metabolic profiles are measurable in patients treated with the approved products axicabtagene ciloleucel and tisagenlecleucel, extending earlier preclinical findings into the clinical setting. In other words, the engineering decision made on a laboratory bench years before infusion leaves a metabolic fingerprint detectable in the bloodstream of treated patients.

Beyond the classic CD28 and 4-1BB dichotomy, the authors survey a growing family of tumour necrosis factor receptor co-stimulatory domains with distinct metabolic signatures. CD27 costimulation supports metabolic fitness by enhancing de novo nucleotide and protein synthesis, and recent work shows it augments both glycolysis and the tricarboxylic acid cycle in third-generation CAR T cells, improving effector function and long-term persistence. OX40 signalling complexes with phosphoinositide 3-kinase to sustain T cell survival and proliferation, and its incorporation into CAR constructs has improved antitumour activity and in vivo persistence in lymphoma models even under repeated antigen stimulation. These findings suggest that rational selection and combination of co-stimulatory domains could be used deliberately as metabolic tuning dials, matching the engineered cell’s energy profile to the demands of a particular tumour type.

Even a perfectly designed CAR T cell, however, must contend with the tumour microenvironment, which the review describes as metabolically hostile. Tumour cells consume glucose avidly, starving infiltrating lymphocytes, while accumulating lactate, adenosine, the oncometabolite 2-hydroxyglutarate and fumarate, all of which suppress T cell function. Hypoxia and nutrient scarcity further erode mitochondrial fitness. The authors catalogue an impressive arsenal of metabolic engineering strategies designed to overcome these barriers. Overexpressing glucose transporters such as GLUT1 or GLUT3 boosts glucose uptake in nutrient-poor tumours, with a recent ‘on-demand’ GLUT3 system in glioblastoma models avoiding the exhaustion problems caused by constitutive overexpression. Engineering fructose transport via GLUT5 gives T cells access to a sugar tumours largely ignore, and a striking fungal-derived cellobiose pathway provides CAR T cells with an alternative fuel source entirely inaccessible to tumour cells. Similar logic has been applied to amino acids, with overexpression of the glutamine transporter ASCT2 enhancing BCMA-targeted CAR T cells in multiple myeloma models, and arginine metabolism engineering improving proliferation in arginine-depleted tumours.

Neutralizing inhibitory metabolites is another active frontier. Overexpression of D-2-hydroxyglutarate dehydrogenase reduces intracellular accumulation of the immunosuppressive oncometabolite and improves antitumour activity, while blocking adenosine signalling through A2A receptor antagonists or engineered adenosine-degrading enzymes protects CAR T cells from this potent immunosuppressive pathway. Even lactate, long viewed purely as a waste product that poisons T cells, is being reconsidered: inhibiting lactate dehydrogenase in combination with interleukin-21 promotes a stem-like state that improves adoptive cell therapy outcomes. Together these approaches illustrate a shift in thinking, from viewing metabolism as a passive constraint to treating it as an engineerable dimension of cell therapy design.

The review then turns to manufacturing, an underappreciated source of metabolic variability. The conditions under which CAR T cells are expanded ex vivo, including the culture medium, cytokine cocktail and expansion platform, imprint distinct metabolic and functional profiles on the final product. Studies have shown that five clinically relevant T cell expansion media activate different metabolic programs, some uncoupled from actual cellular function, and that different expansion platforms yield distinct differentiation states. Reducing ex vivo culture duration improves antileukemic activity, while human plasma-like medium better supports T cell activation. Cytokine choices matter profoundly: interleukin-7 and interleukin-15 favour memory phenotypes and superior antitumour effects compared with conventional interleukin-2, and low interleukin-2 concentrations skew expansion toward early memory cells. Yet despite this evidence, the authors emphasize that metabolic parameters in clinical manufacturing protocols remain largely unstandardized, meaning that two patients receiving nominally identical products may receive cells with substantially different metabolic fitness.

Pharmacological metabolic conditioning during manufacturing offers a further layer of control. Inhibiting PI3K or AKT signalling, or treating cells with rapamycin, can uncouple T cell expansion from differentiation, preserving stem-like, metabolically resilient phenotypes associated with better persistence. Activating the GCN2 stress pathway metabolically reprograms T cells to enhance adoptive cell therapy, while manipulating amino acid availability, including asparagine restriction and methionine regulation, tunes metabolic fitness through stress-response pathways. The authors frame these interventions as part of a continuum: the same metabolic levers available to engineers in the bioreactor are, in principle, also reachable through the patient’s own physiology after infusion.

That bridge leads to the review’s most provocative theme: host metabolism and diet. Malnutrition and cachexia are associated with poor CAR T cell therapy outcomes including survival, and body mass index shows complex associations with response in myeloma patients. Diet-based interventions are clinically accessible and scalable ways to reshape systemic metabolism before and after cell infusion. The evidence base is expanding rapidly. Dietary supplementation with beta-hydroxybutyrate, a ketone body, improved the metabolic fitness and antitumour activity of CAR T cells in mouse models of leukaemia, lymphoma and pancreatic cancer, and a clinical trial of beta-hydroxybutyrate in lymphoma patients is now registered. Very-low-carbohydrate diets have been shown to enhance human T cell immunity through immunometabolic reprogramming, and fasting-mimicking diets are safe in patients with cancer and reshape metabolism and antitumour immunity. Methionine restriction, already being tested in cancer therapy trials, intersects directly with emerging data that early methionine availability attenuates T cell exhaustion.

The authors are careful to note the double-edged nature of dietary manipulation. Ketone metabolism has been implicated in promoting pancreatic cancer progression in some contexts, and the same nutrient deprivation that stresses tumour cells can also stress the therapeutic cells themselves, making timing, duration and tumour-type specificity critical variables. Still, the overall message is one of cautious optimism. By integrating metabolic considerations across the entire therapeutic arc, from co-stimulatory domain selection and transporter engineering through standardized, metabolism-aware manufacturing to deliberate host conditioning through diet, the field may finally overcome the barriers that have kept CAR T cell therapy from fulfilling its promise in solid tumours. Metabolism, long treated as background biology, is emerging as the connective tissue linking CAR design, cell production and patient care, and the review suggests that exploiting it deliberately could unlock durable, effective CAR T cell therapy for a far broader population of patients.

Subject of Research: Metabolic regulation of CAR T cell therapy efficacy in cancer

Article Title: Boosting CAR T cell efficacy in cancer with metabolic insights from design to diet

Article References: Morgan, J., MacPherson, S., & Lum, J. J. (2026). Boosting CAR T cell efficacy in cancer with metabolic insights from design to diet. Nature Reviews Cancer. https://doi.org/10.1038/s41568-026-00984-2

Image Credits: AI Generated

DOI: 10.1038/s41568-026-00984-2

Keywords: CAR T cell therapy, cancer immunotherapy, immunometabolism, co-stimulatory domains, tumour microenvironment, metabolic engineering, cell manufacturing, dietary intervention, ketone bodies, solid tumours, T cell persistence, glucose metabolism

The central challenge the team set out to address is threefold. NK cells expand inefficiently in culture, they persist only briefly after infusion into patients, and the field has historically relied on feeder systems derived from tumor cells to keep them alive and active during manufacturing. Tumor-derived feeders, such as the genetically modified K562 line widely used in expansion protocols, raise obvious regulatory and safety concerns: any residual feeder cells in a final product represent a potential risk, and their use complicates the path to regulatory approval. A tumor-free alternative that can deliver the same potent activating signals would represent a meaningful advance for the entire field of NK cell manufacturing.

The researchers approached the problem by exploiting the developmental plasticity of induced pluripotent stem cells, or iPSCs, which can be reprogrammed from adult cells and directed to become almost any cell type in the body. Rather than differentiating iPSCs directly into NK cells, the team established a hybrid strategy that passes through an intermediate hematopoietic progenitor stage, generating cells known as iHPCs. These progenitors occupy a critical waypoint in blood cell development, possessing the capacity to give rise to mature immune lineages while remaining expandable in culture. By routing differentiation through this stage, the researchers could generate highly pure NK cell populations while simultaneously harvesting the progenitor compartment for a second, unexpected purpose.

That purpose was the creation of iPSC-derived feeder platforms. The team genetically engineered the iHPCs to express two molecules known to sustain NK cell vitality: CD86, a co-stimulatory protein that delivers activating signals through receptors on the NK cell surface, and membrane-bound interleukin-21, a potent NK cell growth factor tethered to the cell membrane rather than secreted into the culture medium. Membrane-bound presentation of cytokines is a well-established trick in the expansion field, because it forces the signal to be delivered through direct cell-to-cell contact, mimicking the physiological interactions that occur in lymphoid tissues and avoiding the exhaustion that can result from chronic exposure to soluble cytokine.

The results of the functional testing were encouraging on several fronts. When co-cultured with primary NK cells, the engineered iHPC feeders expressing CD86 and membrane-bound IL-21 effectively prolonged NK cell survival in vitro, a critical parameter given how quickly unstimulated NK cells lose viability outside the body. The feeders also promoted activation-associated clustering, a behavior in which NK cells physically congregate around stimulating cells, forming immunological synapses that transmit the signals needed to maintain an activated state. This clustering is more than a visual curiosity; it reflects genuine bidirectional communication between the feeder and effector populations and is associated with the metabolic and transcriptional changes that keep NK cells primed for killing.

The study also confronted a persistent problem in iPSC-derived NK cell biology: immaturity. NK cells generated from pluripotent stem cells tend to resemble early developmental stages of the lineage, expressing lower levels of the mature activating receptors that mediate efficient tumor recognition and cytolysis. The researchers found that the iPSC-derived NK cells in their system indeed exhibited an immature phenotype, which would ordinarily limit their therapeutic value. Their solution was to arm the NK cells themselves with stimulatory molecules through genetic modification, creating what the authors describe as a self-feeder strategy in which the therapeutic product carries its own activating apparatus.

Intriguingly, the engineering outcomes were not uniform across the three stimulatory molecules tested. Genetic introduction of CD86 into the iPSC-derived NK cells produced predominant expression and yielded clear functional gains, enhancing activation marker expression and boosting cytotoxic activity against target cells. By contrast, surface expression of membrane-bound IL-21 and 4-1BBL, another co-stimulatory ligand, remained limited despite the genetic modifications. This asymmetry carries practical lessons for the field: not every engineered stimulatory molecule will express at functional levels on iPSC-derived lymphocytes, and construct design, gene delivery method, and genomic integration site all influence whether a given modification translates into meaningful biological activity. The finding that CD86 expression alone was sufficient to potentiate NK cell function suggests that co-stimulation, rather than cytokine presentation, may be the most tractable engineering target in this cellular context.

The implications for scalable manufacturing are considerable. A fully iPSC-based platform offers something that primary blood-derived NK cell products cannot: a theoretically unlimited, genetically uniform starting material. A single well-characterized iPSC master cell bank could, in principle, supply both the therapeutic NK cells and the feeder cells that support their manufacture, eliminating dependence on donor blood draws and on tumor-derived feeder lines in a single stroke. Because iPSCs can be gene-edited with precision before differentiation, desirable traits such as enhanced persistence, resistance to immune suppression in the tumor microenvironment, or armored expression of chimeric antigen receptors could be built into the master line and propagated consistently across every batch. The self-feeder concept demonstrated in this study adds another layer of integration, allowing the same cellular platform to serve both production and activation roles.

Significant hurdles remain before such platforms reach the clinic. The study was conducted in vitro, and the survival and activation benefits observed in culture dishes must be reproduced in animal models and, ultimately, in human trials, where the dynamics of cell persistence, trafficking, and anti-tumor activity play out very differently. The incomplete surface expression of membrane-bound IL-21 and 4-1BBL on the engineered NK cells highlights the technical refinement still needed to optimize the genetic toolkit. Quality control also looms large: any iPSC-based product must be rigorously screened for residual undifferentiated cells, which carry tumorigenic risk, and the genomic stability of engineered lines must be monitored throughout manufacturing. The ethical framework of the study, approved by the Institutional Review Board of Taipei Veterans General Hospital with written informed consent from all participants, reflects the careful governance such work requires as it moves toward translational application.

Even so, the study adds an important piece to the rapidly evolving puzzle of NK cell therapy. By demonstrating that iPSC-derived hematopoietic progenitors can serve as a tumor-free feeder alternative, and that a self-feeder strategy can potentiate the function of otherwise immature iPSC-derived NK cells, the researchers have outlined a manufacturing architecture that is scalable, clinically adaptable, and free of the tumor-derived components that have long complicated regulatory pathways. As demand for off-the-shelf cellular immunotherapies grows, platforms of this kind may prove decisive in determining whether NK cells fulfill their potential as a mainstream cancer treatment, transforming a promising biological insight into a reliable, industrial-scale medicine.

Subject of Research: iPSC-derived feeder cell platforms for enhancing natural killer cell cancer immunotherapy

Article Title: iPSC-derived feeder platforms potentiate natural killer cell Immunotherapy

Article References: Lin, Z.-Q., Sun, Y.-C., Chang, C.-W., Wang, C.-M., Chen, B.-H., Lim, L.-Y., Tsai, Y.-C., Wu, C.-H., Chien, S.-H., Yang, Y.-P., Chiou, S.-H., & Hung, K.-F. (2026). iPSC-derived feeder platforms potentiate natural killer cell Immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04582-x

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04582-x

Keywords: natural killer cells, induced pluripotent stem cells, hematopoietic progenitors, feeder cells, cancer immunotherapy, CD86, membrane-bound IL-21, cell manufacturing, NK cell expansion, adoptive cell therapy, tumor-free feeder, immunotherapy